GlassScriptPhysician profile
Steven G Dimitriou
NPI 1275631632
$3,022.95
in general payments reported to CMS, 2019-2025
22 companies · $776 in 2025
The $776 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $363 · 2020: $194 · 2021: $256 · 2022: $560 · 2023: $397 · 2024: $477 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,650.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $405.80 | 2022-2025 | Ozempic, Rybelsus |
| Amgen INC. | $389.72 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Bayer Healthcare Pharmaceuticals INC. | $307.75 | 2021-2025 | |
| Vifor Pharma, INC. | $271.28 | 2019-2025 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $169.86 | 2019-2025 | Jynarque, Voyxact |
| Fresenius USA Marketing, INC. | $157.43 | 2019-2024 | Velphoro, Korsuva |
| Calliditas Therapeutics US INC. | $150.92 | 2022-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $150.83 | 2019-2024 | Lokelma, Farxiga, Lynparza |
| Novartis Pharmaceuticals Corporation | $148.81 | 2024-2025 | |
| Glaxosmithkline, LLC. | $144.53 | 2022-2024 | Benlysta, Pediarix, Shingrix |
| Opko Pharmaceuticals, LLC | $135.58 | 2020-2024 | Rayaldee |
| Alexion Pharmaceuticals, INC. | $119.75 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.48 | 2023-2025 | Jardiance |
| Ardelyx, INC. | $78.63 | 2024-2025 | Ibsrela |
| Travere Therapeutics, INC. | $69.38 | 2023-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $66.38 | 2020-2025 | Vafseo, Auryxia |
| Horizon Therapeutics Plc | $53.13 | 2022 | |
| Amarin Pharma, INC. | $28.34 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $28.01 | 2022 | |
| Aurinia Pharma U.S., INC. | $20.10 | 2023 | Lupkynis |
| Apellis Pharmaceuticals, INC. | $18.78 | 2025 | Empaveli |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.46 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Dimitriou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.